Recently Featured
Laboratory research in pharmaceutical development

Pharma Access Plans for Low-Income Countries Improve

November 10, 2026
Many large pharmaceutical companies are taking steps to improve access to their medicines in low- and middle-income countries, but progress has been mixed and more action is needed to ensure wide availability, a new analysis found. More drugmakers are planning to reach patients before a product launch — access plans now cover 69% of late-stage…
Scientist working in a biotechnology lab

BIO Proposes Seven-Part Plan to Boost U.S. Drug Development

November 10, 2026
BIO has unveiled a seven-part proposal aimed at accelerating drug development in the U.S. The plan is designed to counter China’s rapid advancements in the biotech sector. The initiatives outlined in the proposal focus on enhancing the U.S. position as a global leader in biotechnology. Specific details of the initiatives were not provided in the…
Stock market decline in pharmaceuticals

Ionis Pharmaceuticals Loses $1 Billion After Tryngolza Sales Cut

November 10, 2026
Ionis Pharmaceuticals lost more than $1 billion in market value after reducing sales projections for its triglyceride-lowering drug, Tryngolza. The company now expects the drug to generate $50 million in sales by the end of this year, down from a previous forecast of $100 to $110 million. During the third quarter, Tryngolza sales reached only…
Scientist working in a laboratory setting

Illumina Launches Early Access Duplex Sequencing for MRD Research

November 10, 2026
Illumina has opened an early access program for a sequencing workflow aimed at studying molecular residual disease (MRD). This research-use-only workflow is designed to detect trace amounts of circulating tumor DNA (ctDNA) in plasma samples and to support longitudinal, whole-genome studies of MRD and tumor evolution. Kits are expected to ship in the first quarter…

Ongoing Cases